IsoRay (ISR) stock: ready for another pop?

IsoRay is a medical company that has developed Cesium-131 as a source for radiation therapy to combat various forms of cancer. In the case of prostate cancer, the company is reviving a procedure called prostate brachytherapy, which involves placing devices containing radiation in the prostate gland close to the cancer cells.

Cesium-131 based brachytherapy solutions show a lot of promise, not only in combating prostate cancer but also in other forms of the disease. With a potential FDA approval, IsoRay has a chance to scale up; however, the company's current financial position is questionable. On July 10, IsoRay did a direct offering of 11 million common shares at $0.75 per share to institutional investors who also received warrants to purchase up to 5.5 million shares at $0.75.
EN English
EN English (UK)
EN English (IN)
DE Deutsch
FR Français
ES Español
IT Italiano
PL Polski
SV Svenska
TR Türkçe
RU Русский
PT Português
ID Bahasa Indonesia
MS Bahasa Melayu
TH ภาษาไทย
VI Tiếng Việt
JA 日本語
KO 한국어
ZH 简体中文
ZH 繁體中文
AR العربية
HE עברית
Home Stock Screener Forex Screener Crypto Screener Economic Calendar How It Works Chart Features House Rules Moderators Website & Broker Solutions Widgets Stock Charting Library Feature Request Blog & News FAQ Help & Wiki Twitter
Profile Profile Settings Account and Billing My Support Tickets Contact Support Ideas Published Followers Following Private Messages Chat Sign Out